Form 4: Instil Bio Director Receives Stock Option Grant
Statement of Changes in Beneficial Ownership
Director Neil W. Gibson was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.
Summary
- Director Neil W. Gibson received a grant of 6,500 stock options for Instil Bio, Inc. (TIL) common stock.
- The options have an exercise price of $7.93 per share.
- The grant date for the transaction was June 11, 2026.
- The options are set to expire on June 10, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- Potential for future shareholder dilution upon the exercise of these stock options.
Risks
- Market volatility affecting the value of the underlying common stock relative to the $7.93 exercise price.
Future Outlook
The options vest in 12 substantially equal monthly installments starting July 11, 2026, with full acceleration upon death, disability, or a change in control.
Management Comments
- The grant is subject to the Reporting Person's Continuous Service as defined in the company's 2021 Equity Incentive Plan.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure leadership remains incentivized during long-term clinical development cycles.
Comparison to Industry Standards
- The use of a 12-month vesting schedule for director options is consistent with standard equity incentive practices for small-cap biotech firms.
- The 10-year expiration term is a standard industry benchmark for executive and director stock option plans.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of stock options to a director under the 2021 Equity Incentive Plan. | 06/11/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Shareholders may experience minor dilution if these options are exercised in the future.
Next Steps
- Vesting of options to commence on July 11, 2026.
- Potential exercise of options by the director subject to market conditions and vesting status.
Key Dates
| Date | Description |
|---|---|
| 06/11/2026 | Date of the stock option grant transaction. |
| 06/12/2026 | Date the Form 4 was filed with the SEC. |
| 07/11/2026 | Commencement date for the 12-month vesting schedule. |
| 06/10/2036 | Expiration date of the granted stock options. |
Keywords
Instil Bio, TIL, Form 4, Insider Trading, Stock Options, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.